skip to Global Navigation Bar
skip to main content
Global Business
Introduction
Strategy
Manufacturing
Licensing Opportunities
Contact Us
R&D
Introduction
Global R D
Pipeline
Our Needs
Products
Products Search
Global Brand
In-License
Introduction
Strategy
No.1 Position
Core-Competency
Licensed Products
Partnership
Investors
Management information
Financial information
Stock condition
IR information
Press Release
News
PR Video
About Us
Company Profile
CEO Message
Recruitment
· News
· PR Video
Home > Press Release >
News
뉴스
No
Subject
Data
225
Daewoong Pharmaceuticals holds a symposium to promote the excellence of Olmesartan medications including ‘Olmetec’ at International Society of Hypertension
2016-09-28
224
Daewoong Pharmaceuticals expands entry to new markets with license in Mexico and India on Nabota
2016-09-22
223
Daewoong Pharmaceuticals disseminates the excellence of ‘Nabota’ in IMCAS
2016-08-02
222
Daewoong Pharmaceuticals signs 29 billion won export contract with Jordan and Iraq
2016-06-30
221
Seoul National University Hospital ? Daewoong Pharmaceuticals sign MOU to commercialize stem cell treatment
2016-06-28
220
Daewoong Pharmaceuticals presents result of phase 3 clinical trial on Supect at The Korean Society of Hematology
2016-05-31
219
Daewoong Pharmaceuticals receives Prime Minister Commendation as an ‘Outstanding Company in Fair Gender Employment’
2016-05-26
218
Daewoong Bio ‘UDCA’ passes EDQM (European Directorate for the Quality of Medicines & Healthcare) inspection
2016-05-26
217
Daewoong Pharmaceuticals invites public officials in drug safety management from 11 countries to its Hyangnam Plant
2016-05-26
216
Daewoong Pharmaceuticals’ Zemiglo increases quarterly sales by twofold compared to last year
2016-05-26
1
/
2
/
3
/
4
/
5
/
6
/
7
/
8
/
9
/
10
/
News Search
subject
content
Home > Press Release > News
Home > Press Release > News